Is NMN Legal in the UK? Current Regulatory Status for 2026

May 19, 2025

By Mathew Stuckey, Founder of Longevity Formulas
Last Updated: December 29, 2025
Author bio

Nicotinamide mononucleotide (NMN) has gained significant interest as a NAD+ supplement in the UK. With increased attention comes regulatory scrutiny. This guide explains the current legal framework for NMN in the UK as of late 2025.

New to NMN? Start with The Complete NMN Guide for everything you need to know.

⚠️ Important: This information is for educational purposes only and should not be considered legal advice. Regulations can change. Always verify current requirements with the Food Standards Agency (FSA) for the most up-to-date information.

Current Legal Status: The Short Answer

NMN is legal to purchase and sell in the UK as of December 2025, but it's classified as a novel food, which means it requires regulatory assessment and compliance with specific requirements.

NMN is not banned or prohibited. However, products containing NMN must meet novel food regulations, and companies selling it must follow specific legal requirements.

What is Novel Food Classification?

The Definition

Under UK law, a novel food is any food or ingredient that wasn't widely consumed in the UK or EU before 15 May 1997. NMN falls into this category because it wasn't commonly used in supplements before this date.

What This Means in Practice

Products containing novel foods require authorisation through the Food Standards Agency (FSA). The authorisation process includes:

Safety assessment based on submitted data
Manufacturing specification review
Stability and quality documentation
Evaluation by food safety experts

Current Status of NMN

As of December 2025, NMN is listed in the UK Novel Foods Catalogue as "under assessment." This means:

Applications for authorisation have been submitted
Products that were on the UK market before certain dates may continue to be sold during the assessment period
Final authorisation decisions are pending

How Brexit Changed NMN Regulation

Before Brexit

The UK followed EU novel food regulations, and authorisations were granted through the European Food Safety Authority (EFSA).

After Brexit

The UK now operates its own novel food system through:

The Food Standards Agency (FSA) for England, Wales, and Northern Ireland
Food Standards Scotland for Scotland

The UK maintained similar core principles to EU regulations but now makes independent decisions on novel food applications.

What "Under Assessment" Means for Consumers

Can I Buy NMN?

Yes. Products containing NMN remain available for purchase whilst under regulatory review.

Are These Products Legal?

Products that were on the market before certain transitional dates can continue being sold during the assessment period, provided they comply with general food safety and labelling requirements.

Will NMN Be Banned?

Based on current regulatory activity, a complete ban appears unlikely. The FSA approach suggests movement toward proper authorisation rather than market removal. However, this isn't guaranteed, and the situation could change as assessments progress.

My Perspective on the Regulatory Situation

Having formulated and sold NMN supplements in the UK for several years, I've watched this regulatory landscape develop closely.

The novel food process is slow and expensive. Small companies struggle with the costs of compiling comprehensive safety dossiers, which can run into six figures. This creates barriers that favour larger corporations, which isn't ideal for innovation or competition.

That said, I understand the regulatory caution. NAD+ precursors interact with fundamental cellular processes. Ensuring long-term safety through proper assessment makes sense, even if the timeline frustrates both companies and consumers.

At Longevity Formulas, we've engaged with the novel food process and maintain compliance with current requirements. We publish Certificates of Analysis for transparency and manufacture under GMP standards because quality matters regardless of regulatory status.

The uncertainty is challenging for businesses, but operating transparently and prioritising quality has been our approach throughout this period.

Requirements for Selling NMN in the UK

Product Requirements

Must be labelled as a food supplement, not a medicine
Cannot make unauthorised health claims (e.g., "treats ageing", "cures disease", "prevents illness")
Must include proper ingredient disclosure
Requires batch identification and expiry dating
Should include appropriate safety warnings

Business Requirements

Companies selling NMN should:

Engage with the novel food authorisation process appropriately
Maintain comprehensive safety and purity documentation
Ensure GMP-compliant manufacturing
Follow UK-specific labelling requirements, not just US or EU standards
Be prepared to demonstrate compliance if questioned by authorities

What to Avoid

UK enforcement has focused on:

Unauthorised medicinal claims in marketing
Inadequate product labelling
Products from non-compliant manufacturing facilities
Marketing materials that present NMN as a medicine rather than a food supplement

Importing NMN to the UK

For Personal Use

Individuals can generally import NMN for personal consumption. However, customs may intercept products that:

Lack proper ingredient disclosure
Make therapeutic claims on packaging
Come from manufacturers with questionable credentials
Contain amounts that suggest commercial rather than personal use

For Commercial Use

Businesses importing NMN for resale face stricter requirements:

Products should be declared or registered appropriately with the FSA
Complete documentation on safety, purity, and manufacturing must be available
Labelling must meet UK supplement standards
Import records should be maintained

Choosing Compliant NMN Products

Quality Indicators

When purchasing NMN in the UK, look for:

Testing and Purity:

Published Certificate of Analysis from accredited laboratory
Minimum 98% purity verification through independent testing
Batch-specific testing documentation

Manufacturing Standards:

GMP-certified manufacturing facilities
Clear identification of manufacturing location
Proper quality control processes

Labelling Compliance:

Clearly marked as food supplement
Complete ingredient listing with amounts
Batch number and expiry date
Appropriate warnings about consulting healthcare providers
No unauthorised health claims

Regulatory Engagement:

Companies that acknowledge novel food status
Transparent about compliance efforts
Willing to provide documentation on request

Red Flags

Be cautious of products that:

Make dramatic health claims
Lack any testing documentation
Come from unknown manufacturers
Are significantly cheaper than pharmaceutical-grade alternatives
Don't clearly identify the company behind them

What Research Shows About NMN Safety

Whilst regulatory authorisation is about legal compliance rather than proven efficacy, the safety data is relevant to understanding why the novel food process exists.

Current Evidence

Human studies up to 12 months show NMN is generally well tolerated
Dosages used in research typically range from 250-1000mg daily
No serious adverse events have been reported in published human trials to date
Animal safety studies have used much higher doses without significant issues

What Remains Unknown

Long-term safety data beyond 12-month periods
Effects in specific populations (pregnant women, children, people with certain medical conditions)
Optimal dosing for different ages and health status
Potential interactions with medications

This is precisely why regulatory assessment exists - to establish comprehensive safety profiles before widespread public use.

The Bigger Picture: Why This Matters

For Consumers

Understanding novel food status helps you:

Make informed decisions about supplement purchases
Identify quality suppliers who take compliance seriously
Understand why prices vary significantly between products
Know what questions to ask suppliers

For the Industry

Regulatory compliance:

Protects consumers from potentially unsafe products
Builds long-term market credibility
Distinguishes serious companies from fly-by-night operators
Establishes quality standards that benefit everyone

My View on Industry Responsibility

Companies selling NMN have a responsibility to operate transparently, even when regulations feel burdensome. Publishing testing results, acknowledging regulatory status openly, and not making exaggerated claims isn't just about legal compliance - it's about building trust in a category that has genuine potential but also attracts opportunistic operators.

The longevity supplement market will only gain credibility if companies prioritise quality and honesty over quick profits.

Looking Forward: What Might Change

Possible Outcomes

Full Authorisation: NMN receives novel food approval with specific conditions on use, labelling, and maximum doses. This would provide regulatory clarity whilst keeping products available.

Conditional Approval: Authorisation granted with restrictions (e.g., maximum daily amounts, specific warnings, limitations on claims).

Ongoing Assessment: The current "under assessment" status continues, maintaining the present situation where products remain available but without final regulatory approval.

Restrictions or Removal: In a less likely scenario, concerns from the assessment could lead to market restrictions or requirements for prescription-only access.

Realistic Expectation

Based on how other novel food applications have proceeded and the safety data accumulated on NMN, full authorisation with appropriate conditions seems the most probable outcome. However, regulatory processes are lengthy, and timelines remain uncertain.

Practical Guidance

If You're Currently Taking NMN

Continue purchasing from reputable suppliers with published testing
Stay informed about regulatory developments
Don't rely solely on NMN if you have genuine health concerns - consult your doctor
Keep products in original packaging with batch numbers in case of recalls

If You're Considering Starting NMN

Research supplier credentials thoroughly
Start with established companies that prioritise transparency
Consult your healthcare provider, especially if you have medical conditions or take medications
Understand that regulatory status could change

If You're Selling NMN

Engage appropriately with FSA requirements
Maintain comprehensive documentation on safety and purity
Ensure labelling meets UK standards
Avoid medicinal claims in all marketing materials
Be prepared for potential regulatory inquiries

Related Information

Our NAD+ supplement range includes NMN products manufactured under GMP standards with published testing documentation. We acknowledge the novel food status and operate in accordance with current UK requirements.

Key Takeaways

NMN is legal to buy and sell in the UK as of December 2025
It's classified as a novel food "under assessment" for authorisation
A complete ban appears unlikely based on current regulatory direction
Products must meet specific labelling and safety requirements
Choose suppliers who demonstrate quality through published testing
Regulatory status could change as assessments progress

Regulatory Notice: This article provides general information about UK regulations as of December 2025. It is not legal advice. Regulations can change, and this information may become outdated. For current requirements, consult the Food Standards Agency directly or seek professional legal advice.

NMN products are food supplements and are not intended to diagnose, treat, cure, or prevent any disease.

Back to blog

Table of contents